Montano Wellness LLC, CT Clinical Research, University of Connecticut Medical School, Farmington, CT, USA.
West Cancer Center, Department of Family Medicine and Department of Psychiatry, University of Tennessee College of Medicine, Memphis, TN, USA.
Postgrad Med. 2023 Jun;135(5):449-465. doi: 10.1080/00325481.2023.2189868. Epub 2023 Apr 5.
Major depressive disorder (MDD) is a debilitating mental disorder that can be treated with a number of different antidepressant therapies, each with its own unique prescribing considerations. Complicating the selection of an appropriate antidepressant for adults with MDD is the heterogeneity of clinical profiles and depression subtypes. Additionally, patient comorbidities, preferences, and likelihood of adhering to treatment must all be considered when selecting an appropriate therapy. With the majority of prescriptions being written by primary care practitioners, it is appropriate to review the unique characteristics of all available antidepressants, including safety considerations. Prior to initiating antidepressant treatment and when patients do not respond adequately to initial therapy and/or exhibit any hypomanic or manic symptoms, bipolar disorder must be ruled out, and evaluation for psychiatric comorbidities must be considered as well. Patients with an inadequate response may then require a treatment switch to another drug with a different mechanism of action, combination, or augmentation strategy. In this narrative review, we propose that careful selection of the most appropriate antidepressant for adult patients with MDD based on their clinical profile and comorbidities is vital for initial treatment selection.Strategies must be considered for addressing partial and inadequate responses as well to help patients achieve full remission and sustained functional recovery. This review also highlights data for MDD clinical outcomes for which gaps in the literature have been identified, including the effects of antidepressants on functional outcomes, sleep disturbances, emotional and cognitive blunting, anxiety, and residual symptoms of depression.
重度抑郁症(MDD)是一种使人衰弱的精神疾病,可以通过多种不同的抗抑郁治疗方法进行治疗,每种方法都有其独特的用药考虑。在为患有 MDD 的成年人选择合适的抗抑郁药时,使情况变得复杂的是临床特征和抑郁亚型的异质性。此外,在选择合适的治疗方法时,还必须考虑患者的合并症、偏好和治疗依从性的可能性。由于大多数处方都是由初级保健医生开具的,因此有必要审查所有可用的抗抑郁药的独特特征,包括安全性考虑。在开始抗抑郁治疗之前,以及当患者对初始治疗反应不足和/或表现出任何轻躁狂或躁狂症状时,必须排除双相情感障碍,并应考虑评估精神合并症。对治疗反应不足的患者可能需要改用另一种作用机制、联合用药或增效策略不同的药物。在本叙述性综述中,我们提出,根据患者的临床特征和合并症,仔细选择最适合患有 MDD 的成年患者的抗抑郁药对于初始治疗选择至关重要。必须考虑解决部分和不充分反应的策略,以帮助患者实现完全缓解和持续的功能恢复。该综述还强调了 MDD 临床结果的数据,其中确定了文献中的空白,包括抗抑郁药对功能结果、睡眠障碍、情绪和认知迟钝、焦虑和抑郁残留症状的影响。